The U.S. Food and Drug Administration (FDA) has approved the BTL Vanquish for circumferential reduction of the abdomenal area. The platform features a panel array that emits selective RF energy with the largest spot size in the industry to treat the entire core in one application (without touching patients’ skin). It creates a high-frequency energy field that targets the thermal effects into the fat layer while protecting surrounding skin tissue. “FDA clearance of BTL Vanquish marks a defining moment in our journey to provide physicians and their patients an elegant treatment option to target fat cells and bring about a reduction in the waist circumference,” says Andrea Morrison, BTL director of clinical development. “BTL is proud to offer patients a comfortable, affordable and noninvasive body shaping experience. This regulatory milestone underscores BTL’s commitment to deliver meaningful solutions to aesthetic patient care.”